07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

Japanese cedar tree pollen Allergy Immunotherapy Tablet: Phase II/III data

A double-blind, Japanese Phase II/III in about 1,000 patients with Japanese cedar tree pollen-induced allergic rhinitis showed that sublingual TO-206 met the primary endpoint of improving TCRS vs. placebo. TO-206 was well tolerated. ALK-Abello said...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

Japanese cedar tree pollen allergy immunotherapy tablet: Phase II/III started

ALK-Abello said partner Torii began a Japanese Phase II/III trial to evaluate TO-206 in about 1,000 patients with Japanese cedar tree pollen-induced allergic rhinitis. Torii and ALK-Abello are partnered to develop the product under a...